Vanguard Group Inc. Has $226.02 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS

Posted by Anthony Miller on Mar 2nd, 2026

Vanguard Group Inc. lessened its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 1.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,987,394 shares of the company’s stock after selling 167,357 shares during the period. Vanguard Group Inc. owned about 0.08% of Apellis Pharmaceuticals worth $226,015,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Apellis Pharmaceuticals by 207.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock valued at $667,000 after purchasing an additional 19,944 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Apellis Pharmaceuticals by 26.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after acquiring an additional 64,742 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Apellis Pharmaceuticals by 4.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock valued at $4,869,000 after acquiring an additional 9,747 shares during the period. Focus Partners Wealth raised its position in Apellis Pharmaceuticals by 118.4% in the first quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock worth $479,000 after purchasing an additional 11,862 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in Apellis Pharmaceuticals by 1,146.2% during the first quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock worth $522,000 after purchasing an additional 22,052 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $20.96 on Monday. The firm has a fifty day moving average of $23.00 and a two-hundred day moving average of $23.77. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.70 and a current ratio of 3.14. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 161.24 and a beta of 0.26. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $30.48.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The firm had revenue of $199.91 million for the quarter, compared to analyst estimates of $199.28 million. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. The company’s quarterly revenue was down 5.9% on a year-over-year basis. As a group, equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

Positive Sentiment: HC Wainwright retains a “Buy” rating and a $48 price target, signaling continued analyst conviction in Apellis’ longer‑term upside. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Positive Sentiment: HC Wainwright published a long‑range forecast that includes a return to positive EPS by FY2030 (EPS ~$1.97), which underpins the firm’s $48 target and suggests expected recovery beyond the near term. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Neutral Sentiment: Apellis’ latest quarter delivered an EPS beat ($0.47 vs. expectations) but revenue was down ~6% year‑over‑year — a mixed fundamental print that reduces downside surprise risk but highlights demand pressure.
Neutral Sentiment: Reported short‑interest data in recent filings appears anomalous (zero / NaN entries) and is not a reliable signal of investor positioning at this time.
Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (e.g., FY2026 cut to ~($2.19) from ($1.69); FY2027, FY2028 and several quarterly estimates were also reduced), increasing near‑term earnings uncertainty and pressuring the stock. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Negative Sentiment: Citigroup trimmed its price target to $44, signaling reduced upside in the nearer term and contributing to downward pressure. Citigroup Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $44.00
Negative Sentiment: Wedbush and Royal Bank of Canada also lowered expectations, adding to the analyst‑driven sell pressure. Wedbush Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Royal Bank Of Canada Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price

Analyst Ratings Changes

Several research firms recently commented on APLS. Wolfe Research started coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating for the company. Weiss Ratings restated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. Cantor Fitzgerald reduced their price target on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $19.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. Finally, Stifel Nicolaus cut their price objective on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, December 19th. Twelve equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $32.61.

Read Our Latest Report on APLS

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,797 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $60,890.69. Following the completion of the transaction, the insider directly owned 86,527 shares of the company’s stock, valued at approximately $1,883,692.79. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pascal Deschatelets sold 5,928 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $129,052.56. Following the completion of the transaction, the insider directly owned 1,151,382 shares in the company, valued at approximately $25,065,586.14. The trade was a 0.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,537 shares of company stock worth $2,608,532 in the last three months. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Profile

(Free Report)

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.